NUBRATORI, INC.
Drug class
Agents to Treat Erectile Dysfunction,Adrenergic Blocking-Typ
The phrase "Agents to Treat Erectile Dysfunction,Adrenergic Blocking-Typ" represents a formulary or database classification descriptor rather than a standardized, established medical consensus drug class. Read more about Agents to Treat Erectile Dysfunction,Adrenergic Blocking-Typ
3 drugs in this class 2 manufacturers
Drugs in Agents to Treat Erectile Dysfunction,Adrenergic Blocking-Typ
EMPOWER PHARMAC
EMPOWER PHARMAC
Filter & compare in the drug finder →
Opens the drug finder with Agents to Treat Erectile Dysfunction,Adrenergic Blocking-Typ preselected. Add indication or manufacturer filters there.
The phrase "Agents to Treat Erectile Dysfunction,Adrenergic Blocking-Typ" represents a formulary or database classification descriptor rather than a standardized, established medical consensus drug class.
In clinical pharmacology, this grouping corresponds to adrenergic receptor antagonists—primarily alpha-adrenergic blocking agents such as phentolamine or yohimbine—utilized in the management of male erectile dysfunction.
These agents function by antagonizing adrenergic receptors in penile cavernosal tissue or the central nervous system, reducing sympathetic vasoconstrictor tone to promote smooth muscle relaxation, arterial inflow, and lacunar engorgement.
Historically, their primary therapeutic application in this setting has been the management of erectile insufficiency, administered either orally or via intracavernosal injection regimens.
-
researchgate.net
The phrase "Agents to Treat Erectile Dysfunction,Adrenergic Blocking-Typ" represents a formulary or database classification descriptor rather than a standardized, established medical consensus drug class In clinical pharmacology, this grouping corresponds to adrenergic receptor antagonists—primarily alpha-adrenergic blocking agents such as phentolamine or yohimbine—utilized in the management of male erectile dysfunction These agents function by antagonizing adrenergic receptors in penile caverno...
-
patientcareonline.com
In clinical pharmacology, this grouping corresponds to adrenergic receptor antagonists—primarily alpha-adrenergic blocking agents such as phentolamine or yohimbine—utilized in the management of male erectile dysfunction These agents function by antagonizing adrenergic receptors in penile cavernosal tissue or the central nervous system, reducing sympathetic vasoconstrictor tone to promote smooth muscle relaxation, arterial inflow, and lacunar engorgement
-
auanet.org
In clinical pharmacology, this grouping corresponds to adrenergic receptor antagonists—primarily alpha-adrenergic blocking agents such as phentolamine or yohimbine—utilized in the management of male erectile dysfunction Historically, their primary therapeutic application in this setting has been the management of erectile insufficiency, administered either orally or via intracavernosal injection regimens
-
google.com
These agents function by antagonizing adrenergic receptors in penile cavernosal tissue or the central nervous system, reducing sympathetic vasoconstrictor tone to promote smooth muscle relaxation, arterial inflow, and lacunar engorgement
-
nih.gov
Historically, their primary therapeutic application in this setting has been the management of erectile insufficiency, administered either orally or via intracavernosal injection regimens
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.